LDC and ISAR Bioscience Team up to Develop Novel Regenerative Therapies

Combining stem cell and genomic engineering know-how to generate next generation disease models with proven integrated drug discovery capabilities and global industry network will further diversify our portfolio and serve our mission to translate scientific breakthroughs into therapies.
PLANEGG, Germany - Aug. 5, 2019 - PRLog -- Lead Discovery Center (LDC) and ISAR Bioscience GmbH signed a collaboration agreement to jointly develop new therapeutics in the fields of regenerative medicine using state-of-the-art stem cell technologies. A special focus will be in the therapeutic area of neurodegeneration. Using their combined expertise, capabilities and resources, the partners will jointly advance high-potential projects from academic stage up to clinical trials.

Projects will be sourced from the partners' own project portfolios and their academic networks, spanning a broad range of universities, university hospitals and research institutions. ISAR and LDC will cooperate closely throughout the drug discovery process in alignment with their academic partners. ISAR will contribute its leading stem cell and genomic engineering know-how to generate the next generation of disease models and assay technologies that will improve drug discovery and lead validation processes as well as patient stratification in clinical trials. The LDC will use its proven integrated drug discovery capabilities and leverage its global industry network for subsequent commercialization.

"With our highly synergistic competencies, we are perfectly positioned to unlock the potential of regenerative medicine," says Bert Klebl, CEO of the LDC. "We can start right away, and we are very much looking forward to launching our first joint projects."

Ulrich Gerth, CEO of ISAR, continues: "Applied stem cell biology and genome engineering technologies have advanced enormously and enable therapeutics discovery for complex diseases. We currently forge strategic partnerships with industry partners in priority areas to translate our key technologies into therapies. The agreement with the LDC is a very valuable, complementary addition to diversify our portfolio and increase ISAR's bandwidth."

Media Contacts

Dr. Bert Klebl
CEO, Lead Discovery Center
E-mail: pr@lead-discovery.de
Tel: +49 (231) 974270 00

Dr. Ulrich C. Gerth
CEO, ISAR Bioscience GmbH
E-mail: info@isarbioscience.de
Tel: +49 (89) 356475 400

About the LDC

Lead Discovery Center (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need.

The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the LDC is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential.  The LDC sustains a strong partnership with the Max Planck Society, has licensed assets and formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi-Sankyo, Qurient, Johnson&Johnson Innovation, Sotio, RaND, Apeiron Biologics and Gruenenthal as well as leading translational drug discovery centres around the globe.


About ISAR Bioscience GmbH

ISAR Bioscience GmbH (ISAR:Institute for Stem Cell & Applied Regenerative Medicine Research) overcomes current limitations of stem cell research to advance discovery of novel therapeutics and industrial biotechnology solutions and products. ISAR uses human induced pluripotent stem cell (hiPSC) and genome engineering technologies to build the next generation of disease models for drug discovery and regenerative medicine as well as cellular models that emulate the human senses. As progressive translational research hub, ISAR forges strategic partnerships with industry partners to immediately translate academic achievements and ideas into industrial solutions and products under one roof.

ISAR was founded in 2018 by scientists, drug discovery professionals, and science entrepreneurs who share the passion that immediate translation of scientific discoveries offers an unprecedented opportunity to discover and develop effective pharmaceutical therapeutics as well as industrial biotechnology products and at the same time enhance economic productivity of knowledge societies.

ISAR attracted an initial 20 Mio € funding from the Bavarian Ministry of Economic Affairs, Regional Development and Energy to support ISAR's translational R&D concept. Part of this substantial support will be dedicated for joint projects within the ISAR collaboration framework.


Media Contact
ISAR Bioscience GmbH
+49 89 356475 400
Posted By:***@isarbioscience.de Email Verified
Tags:Regenerative Medicine, Ipsc, Stem Cells, translational R&D, Disease Models, Therapeutics Discovery, Neurodegeneration, Genome engineering
Industry:Biotech, Research, Science
Location:Planegg - Bavaria - Germany
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share